As earlier mentioned, it is likely that milder activation protocols would better reflect the reality of in vivo neuroinflammation occurring in patients with neurodegenerative disease, stroke, etc. Our data provide evidence that A2AR antagonists and A3R agonists can lead to the neuroprotective phenotype, although commonly used biomarkers indicate otherwise. Here, ADORA2A is linked to stroke disorder.